SMS Pharmaceuticals Ltd Q4 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Published 31 May 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹3.4K Cr
FY27 revenue growth guidance is 15%, adopting a prudent approach due to geopolitical uncertainties impacting logistics and supply chains. FY27 revenue growth guidance is 15%, with a conservative outlook due to geopolitical uncertainties; potential to exceed if environment stabilizes.
From SMS Pharmaceuticals Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Price
₹357
Market Cap
₹3.4K Cr
P/E Ratio
33.3
Revenue Rank
Margin Rank
How does SMS Pharmaceuticals Ltd rank in Pharmaceuticals & Biotechnology?
Compare SMS Pharmaceuticals Ltd against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.
SMS Pharmaceuticals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹238 Cr, net profit ₹21 Cr.
Full financials →📊 Revenue & Sales Performance
Rank 3- →FY27 revenue growth guidance is 15%, adopting a prudent approach due to geopolitical uncertainties impacting logistics and supply chains.
- →If external environment stabilizes, growth could exceed current guidance thanks to strong product opportunities.
- →Targeted long-term growth rate is 20%-25% annually post-FY27.
- →Installed capacity to increase to 800 metric tons per month by FY27-end; high utilization expected by FY28, supporting volume growth.
- →Continued focus on expanding product portfolio including 4-5 new APIs and brownfield expansion expected to contribute significantly from FY28 onwards.
- →Backward integration (notably ibuprofen) to improve margins and sales sustainability.
- →Peptide platform and CDMO initiatives expected to become meaningful growth drivers from FY29 onwards.
- →Strengthening of high-value product share targeted to increase from current ~47% to ~60% in medium term.
📈 Profitability & Margins
Rank 1- →FY27 revenue growth guidance is 15%, with a conservative outlook due to geopolitical uncertainties; potential to exceed if environment stabilizes.
- →Target EBITDA margin for FY27 is around 22%, up from 20% in FY26, driven by backward integration and new high-margin APIs.
- →The company aims for 20%-25% growth rate from FY28 onwards, supported by capacity expansion and new product launches.
- →Brownfield expansion (INR280 crores capex) expected to contribute meaningfully from FY28, with scale-up in FY29.
- →Peptides and CDMO initiatives are medium-term growth drivers, with significant contributions anticipated from FY29.
- →PAT rose 47% in FY26; sustained margin improvements and volume growth expected to drive future earnings growth.
- →Strong focus on operational excellence, new product pipeline, and diversification to maintain higher margins and profits.
🏗️ Capital Expenditure Plans
Yes- →Ongoing brownfield expansion project with a planned investment of approximately INR 280 crores; INR 130 crores already invested.
- →Expansion includes building a dedicated block for 4-5 new high-margin APIs to support commercialization.
- →Increasing ibuprofen backward integration capacity from 500 to 800 metric tons per month; current capacity utilization around 80%.
- →Capex work expected to be completed by March FY27; incremental revenues anticipated from FY28.
- →Focus on backward integration to improve margins and stabilize supply, especially for key products like ibuprofen.
- →Investments in peptides R&D with medium-term commercial contributions expected from FY29 onwards.
- →Continued evaluation and development of CDMO initiatives with updates planned after the next two quarters.
💰 Fundraising & Capital Structure
No information📋 Order Book & Pipeline
No information- →The transcript does not explicitly mention the current or expected order book or pending orders in specific terms.
- →There is mention of strong growth and high capacity utilization, particularly for anti-inflammatory APIs, with a significant portion of planned capacity already committed for the coming year.
- →The company expects capacity utilization to reach a high level by FY28 after completion of capex in FY27.
- →New product filings and expansions (including 12 DMFs filed in FY26 and plans for 10 filings in FY27 and FY28 each) indicate a healthy pipeline for future orders.
- →Joint venture products are being developed and expected to commercialize within the financial year, supporting new order inflows.
- →No direct quantification of the order book was provided during the call.
Key Metrics
Revenue
Margin
Capex
Fundraise
Order Book
Frequently Asked Questions
What were SMS Pharmaceuticals Ltd Q4 FY26 results?
FY27 revenue growth guidance is 15%, adopting a prudent approach due to geopolitical uncertainties impacting logistics and supply chains. FY27 revenue growth guidance is 15%, with a conservative outlook due to geopolitical uncertainties; potential to exceed if environment stabilizes.
What is SMS Pharmaceuticals Ltd share price analysis?
SMS Pharmaceuticals Ltd currently shows a below-average growth signal. The stock trades at a P/E of 33.3 with a market cap of ₹3,414 Cr. Investors should review the full earnings analysis for detailed insights.
Is SMS Pharmaceuticals Ltd planning capital expenditure?
Ongoing brownfield expansion project with a planned investment of approximately INR 280 crores; INR 130 crores already invested.
Keep SMS Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.